中联品牌怎么样 申请店铺

我要投票 中联在医疗器械行业中的票数:612 更新时间:2026-01-23
中联是哪个国家的品牌?「中联」是 国药集团中联药业有限公司 旗下著名品牌。该品牌发源于湖北省武汉市,由创始人蒋焘在1998-04-09期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力中联品牌出海!将品牌入驻外推网,定制中联品牌推广信息,可以显著提高中联产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

中联怎么样

国药中联有着悠久的历史,由拥有四百余年中医药历史并享誉全国的叶开泰、达仁堂、刘有余堂金同仁、九芝堂、陈太乙等为代表的192家中药店铺联合组建而成。1952年,在原武汉市中药饮片业同业公会的发动下,成立武汉市中联制药厂。1997年股份制改造,2002年成立集团公司,2011年底重组进入中国较大的健康产业平台――中国医药集团。经过60余年发展壮大,公司已形成包括中成药、化学制剂生产和销售、医药商业营运等在内的多种产业结构,成为集科研、生产、流通、外贸于一体的专业医药健康企业。

公司专注经典中药生产与销售。拥有注册产品300余个,有82个品种列入国家基本药物目录,有14个品种,其中战略大品种鳖甲煎丸有两千多年历史,为汉代张仲景经典古方,专治胁下癥块。公司产品涉足肝脏用药、呼吸系统用药、妇科用药、心脑血管用药等特色领域,已形成以鳖甲煎丸为代表的肝脏用药系列,以金叶败毒颗粒、鼻炎片、强力感冒片为代表的呼吸道用药系列,以脉君安片、心脑清软胶囊为代表的心脑血管用药系列,以加味生化颗粒为代表的妇科用药系列。

公司注重经典中药的系统深度开发。依托国药集团旗下中国医药工业研究总院研发平台,广泛开展国内、国际合作与交流,不断探索经典古方治病机理,研究新工艺,保障产品疗效,拥有多项自主知识产权,为公司的可持续发展奠定了坚实地基础。

公司营销网络遍布全国多省、自治区、直辖市,终端销售网点覆盖全国,主要品种出口日本、马来西亚、印尼、美国等国家和地区。公司不仅销售产品,同时专注于将中医药哲学(文化)、产品核心价值传递给医生和患者,使“中联”成为受医生和患者尊重的制药企业,为中国中医药的发展贡献力量。

公司在东湖高新技术开发区光谷生物城按照现代中药生产标准兴建的“中联中医药产业园”已经建成,未来,公司将以此为依托,以“挖掘传承创新发扬中国中药,为‘家人’提供经典好中药”为已任,传承发扬中国中药,力争成为国内优秀现代化中药企业。十三五末营业收入过十亿元,利润过亿元。


Sinopharm has a long history. It is composed of 192 traditional Chinese medicine stores represented by Ye Kaitai, Da Rentang, Liu youyutang, Jin Tongren, Jiuzhitang and Chen Taiyi, who have more than 400 years of traditional Chinese medicine history and are well-known throughout the country. In 1952, Wuhan Zhonglian pharmaceutical factory was established under the initiative of the former Wuhan herbal medicine industry association. In 1997, the joint-stock system was reformed, and the group company was established in 2002. At the end of 2011, it was reorganized into China's larger health industry platform, China Pharmaceutical Group. After more than 60 years of development and expansion, the company has formed a variety of industrial structures, including the production and sales of Chinese patent medicine, chemical preparations, pharmaceutical commercial operation, etc., and has become a professional pharmaceutical health enterprise integrating scientific research, production, circulation and foreign trade. The company focuses on the production and sales of classic Chinese medicine. There are more than 300 registered products, 82 varieties are listed in the national basic drug catalog, and 14 varieties, of which the strategic big variety Biejiajian Pill has a history of more than 2000 years. It is a classic ancient recipe of Zhang Zhongjing in Han Dynasty and specializes in treating hypochondriac diseases. The company's products are involved in the fields of liver medicine, respiratory system medicine, gynecology medicine, cardio cerebral vascular medicine, etc. it has formed a series of liver medicine represented by Biejiajian Pill, respiratory medicine represented by Jinyebaidu granule, Biyan tablet, qiangliganmao tablet, cardio cerebral vascular medicine represented by maijunan tablet and xinnaoqing soft capsule, and Jiawei biochemical granule The representative series of gynecological medicine. The company pays attention to the systematic and in-depth development of traditional Chinese medicine. Relying on the R & D platform of China Pharmaceutical Industry Research Institute under Sinopharm group, the company has extensively carried out domestic and international cooperation and exchanges, constantly explored the mechanism of classical ancient prescriptions, studied new technologies, guaranteed the product efficacy, and possessed a number of independent intellectual property rights, laying a solid foundation for the company's sustainable development. The company's marketing network covers many provinces, autonomous regions and municipalities directly under the central government, and the terminal sales outlets cover the whole country. The main products are exported to Japan, Malaysia, Indonesia, the United States and other countries and regions. The company not only sells products, but also focuses on delivering the Philosophy (Culture) and core values of traditional Chinese medicine to doctors and patients, making Zoomlion a pharmaceutical enterprise respected by doctors and patients and contributing to the development of traditional Chinese medicine in China. The "Zhonglian traditional Chinese medicine industrial park" built by the company in the Guanggu biological city of Donghu high tech Development Zone in accordance with the production standards of modern traditional Chinese medicine has been completed. In the future, the company will take this as the support, take "mining, inheriting, innovating and carrying forward Chinese traditional medicine, providing classic and good traditional Chinese medicine for" family "as the responsibility, inherit and carry forward Chinese traditional medicine, and strive to become an excellent modern Chinese medicine enterprise in China. At the end of the 13th five year plan, the operating revenue was over one billion yuan and the profit was over one billion yuan.

本文链接: https://brand.waitui.com/9f77d79a5.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

证监会进一步扩大期货市场开放品种范围

36氪获悉,证监会根据《境外交易者和境外经纪机构从事境内特定品种期货交易管理暂行办法》(证监会令第116号)的有关规定,新增确定14个期货期权品种为境内特定品种。具体包括:上海期货交易所镍期货、镍期权;郑州商品交易所对二甲苯期货、瓶片期货、短纤期货、精对苯二甲酸期权、对二甲苯期权、瓶片期权、短纤期权;广州期货交易所碳酸锂期货、碳酸锂期权;上海国际能源交易中心20号胶期权、低硫燃料油期权、国际铜期权。

2小时前

首驱成为2026央视春晚官方智能出行战略合作伙伴

36氪获悉,今日,首驱与中央广播电视总台达成战略合作,正式成为2026年总台春晚官方智能出行战略合作伙伴。

2小时前

2连板钧达股份:钙钛矿光伏技术在太空极端环境下的综合成本效益仍有待验证

36氪获悉,钧达股份公告,太空光伏行业目前仍处于技术探索阶段,未来市场空间与产业化节奏存在较大不确定性,若未来出现更具竞争力的技术路线,或竞争对手率先实现技术突破与规模化应用,可能对目标公司的市场地位带来挑战。本次投资属于早期参股投资,目标公司为新设主体,尚无自主经营历史与完整财务数据,未来经营成果、盈利能力及估值成长均存在较大不确定性,公司能否通过本次投资实现预期收益或顺利退出存在风险。

2小时前

华为鸿蒙系统过国测,铠大师用户已突破10万

36氪获悉,华为HarmonyOS V1.0桌面操作系统近日获得中国信息安全测评中心Ⅱ级安全可靠认证;晟为数科铠大师虚拟机个人用户量也已突破10万。

2小时前

北汽蓝谷:子公司拟投资19.91亿元建设享界超级工厂高端平台车型产业化及产线数智化提升项目

36氪获悉,北汽蓝谷公告,公司子公司北京新能源汽车股份有限公司拟投资建设享界超级工厂高端平台车型产业化及产线数智化提升项目,投资金额为19.91亿元。旨在通过产线升级、数智化应用、工艺拓展车型生产能力等,导入BE22 3.0平台及三款车型,全方位提升制造体系的柔性化、效率、质量和智能化水平。本项目建设期为14个月,预计开工时间为2026年3月。

2小时前

本页详细列出关于中联的品牌信息,含品牌所属公司介绍,中联所处行业的品牌地位及优势。
咨询